Full Text View
Tabular View
No Study Results Posted
Related Studies
PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)
This study has been completed.
Study NCT00221702   Information provided by University Hospital, Bordeaux

First Received on September 13, 2005.   Last Updated on October 12, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma
Neoplasm Metastasis
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neoplastic Processes
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Pathologic Processes
Interventions listed in this trial
PegIntron
intron A
Additional drug interventions recognized in this trial
Interferon Alfa-2b
Peginterferon alfa-2b
Reaferon
More general drug interventions related to this trial
Adjuvants, Immunologic
Alcohol Deterrents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University Hospital, Bordeaux
Schering-Plough


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services